Everything below concerns reversed-phase HPLC. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-07-17. Numbers and descriptions here follow the published literature rather than marketing material.
Body composition is assessed with dual-energy X-ray absorptiometry or comparable methods, which separate fat mass from lean mass. Reported losses include both compartments, and the ratio between them is a subject of ongoing analysis rather than a settled result. Waist circumference, blood pressure, and lipid panels are collected as supporting measures. Resting energy expenditure and substrate oxidation are measured in smaller mechanistic studies, where glucagon receptor activity is expected to matter. These substudies are typically short and small, so their findings carry wide uncertainty.
Interpretation depends on study phase and duration. Phase 2 programs are powered for weight and safety signals, not for cardiovascular or renal outcomes, which require event-driven designs. Gastrointestinal events such as nausea, diarrhea, vomiting, and constipation are the most frequently reported adverse effects and tend to cluster around dose escalation. Small increases in heart rate have been described. Because follow-up after treatment discontinuation is limited, questions about weight regain and durability are open rather than answered.
Trial reports for this compound rely on a small set of repeated measures. Body weight is normally expressed as percent change from baseline at a fixed week, with absolute kilograms given secondarily. Glycemic endpoints include HbA1c, fasting glucose, and, in some protocols, continuous glucose monitoring summaries. Imaging endpoints such as MRI-derived proton density fat fraction quantify liver fat. Standardization matters because a percent change and a categorical responder analysis can tell different stories about the same dataset.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
| Property | Value | Notes |
|---|---|---|
| Trial design | Randomized, double-blind, placebo-controlled | Frequently includes dose-escalation arms |
| Weight endpoint | Percent change from baseline | Reported at a prespecified week |
| Liver fat endpoint | MRI proton density fat fraction | Non-invasive imaging measure |
| Body composition method | Dual-energy X-ray absorptiometry | Separates fat mass from lean mass |
| Common adverse events | Nausea, diarrhea, vomiting | Reported most often during dose escalation |
Identity and purity are established by instrumental methods rather than by appearance. Reversed-phase high-performance liquid chromatography separates the peptide from related impurities and yields a purity value, usually expressed as the share of total peak area. Mass spectrometry checks that the observed mass agrees with the mass calculated from the published sequence, while peptide mapping or amino acid analysis adds structural evidence. Water content, counter-ion identity and residual solvents are sometimes reported as well. A certificate of analysis should name the method behind each figure, because results are method-dependent.
Laboratory handling follows the conventions used for other synthetic peptides. Lyophilized material is weighed and dissolved in an aqueous diluent, typically sterile water or bacteriostatic water, using gentle swirling rather than vigorous shaking, because foaming stresses the chain. Solutions are prepared under clean conditions and, where sterility matters, passed through a suitable filter. Working portions are kept small so that stock material is not repeatedly warmed and cooled, a practice that limits both aggregation and gradual loss of activity.
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
Characterization panels may add amino acid analysis for compositional confirmation, circular dichroism for secondary structure in solution, and light scattering for aggregation tendency. Aggregation is a central concern for peptides bearing hydrophobic side chains, since it can lower measured potency and complicate accurate dosing. Stability studies examine temperature, humidity, pH, and light exposure over defined intervals, reporting the percentage of intact peptide remaining. Results depend strongly on the assay used, so comparing values across studies requires matching method details.
Peptide content and purity are commonly measured by reversed-phase high-performance liquid chromatography with ultraviolet detection, using gradient elution over a C18 column. Identity is confirmed by mass spectrometry, because the theoretical monoisotopic mass allows unambiguous assignment of the main component. Impurity profiling resolves deletion sequences, oxidized residues, and truncated fragments. Since the molecule carries a lipophilic side chain, mobile phases often include ion-pairing agents and organic modifiers to keep peaks symmetric.
Lyophilized material is generally held at minus 20 degrees Celsius or colder for long-term storage, protected from moisture and light. Solutions are handled under refrigeration, typically between 2 and 8 degrees Celsius, and used within a short window because degradation and microbial growth both accelerate in liquid. Repeated freeze-thaw cycles are avoided, and vials are equilibrated to room temperature before opening to reduce condensation. These are general laboratory conventions for peptides of this size rather than product-specific directions.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
=== Allies and Associated Powers === The declaration was first endorsed by a foreign government on 27 December 1917, when Serbian Zionist leader and diplomat David Albala announced the support of Serbia's government in exile during a mission to the United States. The French and Italian governments offered their endorsements in 1918. At a private meeting in London on 1 December 1918, Lloyd George and French Prime Minister Georges Clemenceau agreed to certain modifications to the Sykes–Picot Agreement, including British control of Palestine. On 25 April 1920, the San Remo conference – an outgrowth of the Paris Peace Conference attended by the prime ministers of Britain, France and Italy, the Japanese Ambassador to France, and the United States Ambassador to Italy – established the basic terms for three League of Nations mandates: a French mandate for Syria, and British mandates for Mesopotamia and Palestine. With respect to Palestine, the resolution stated that the British were responsible for putting into effect the terms of the Balfour Declaration. The French and the Italians made clear their dislike of the "Zionist cast of the Palestinian mandate" and objected especially to language that did not safeguard the "political" rights of non-Jews, accepting Curzon's claim that "in the British language all ordinary rights were included in "civil rights"". At the request of France, it was agreed that an undertaking was to be inserted in the mandate's procès-verbal that this would not involve the surrender of the rights hitherto enjoyed by the non-Jewish communities in Palestine.
Sulfur forms over 30 solid allotropes, more than any other element. Besides S8, several other rings are known. Removing one atom from the crown gives S7, which is of a deeper yellow than S8. HPLC analysis of "elemental sulfur" reveals an equilibrium mixture of mainly S8, but with S7 and small amounts of S6. Larger rings have been prepared, including S12 and S18. Amorphous or "plastic" sulfur is produced by rapid cooling of molten sulfur—for example, by pouring it into cold water. X-ray crystallography studies show that the amorphous form may have a helical structure with eight atoms per turn. The long coiled polymeric molecules make the brownish substance elastic, and in bulk it has the feel of crude rubber. This form is metastable at room temperature and gradually reverts to the crystalline molecular allotrope, which is no longer elastic. This process happens over a matter of hours to days, but can be rapidly catalyzed.
== External links == nobelprize.org Explaining the function of eukaryotic elongation factors Elongation+Factor at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Peptide+Elongation+Factor+G at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Peptide+Elongation+Factor+Tu at the U.S. National Library of Medicine Medical Subject Headings (MeSH) EC 3.6.5.3
Records of slavery in Ancient Greece begin with Mycenaean Greece. Classical Athens had the largest slave population, with as many as 80,000 in the 6th and 5th centuries BC. As the Roman Republic expanded outward, entire populations were enslaved, across Europe and the Mediterranean. Slaves were used for labour, as well as for amusement (e.g., gladiators and sex slaves). This oppression by an elite minority eventually led to slave revolts (see Roman Servile Wars); the Third Servile War was led by Spartacus. By the late Republican era, slavery had become an economic pillar of Roman wealth, as well as Roman society. It is estimated that 25% or more of the population of Ancient Rome was enslaved, although the actual percentage is debated by scholars and varied from region to region. Slaves represented 15–25% of Italy's population, mostly war captives, especially from Gaul and Epirus. Estimates of the number of slaves in the Roman Empire suggest that the majority were scattered throughout the provinces outside of Italy. Generally, slaves in Italy were indigenous Italians. Foreigners (including both slaves and freedmen) born outside of Italy were estimated to have peaked at 5% of the total in the capital, where their number was largest. Those from outside of Europe were predominantly of Greek descent. Jewish slaves never fully assimilated into Roman society, remaining an identifiable minority. These slaves (especially the foreigners) had higher death rates and lower birth rates than natives and were sometimes subjected to mass expulsions.
== In popular culture == Dorothy L. Sayers's short story "The Leopard Lady", in the 1939 collection In the Teeth of the Evidence, features a child poisoned by potato berries injected with solanine to increase their toxicity. Inio Asano named one of his manga after the chemical: Solanin.
Sources: en.wikipedia.org
=== Polymer chemistry === Although MS-based analyses of polymers have largely been performed using single-stage MS, tandem MS has also been used to characterize polymer components. CID is the most common method of dissociation used, but ETD has been used as a complementary method. Unique bond cleavages resulting from ETD supply valuable diagnostic information.
=== Arcade Mode === The 1.7 update included the Arcade Mode, which added three new game modes: Survival, The Night Watch, and Sandbox. The player can save while in Survival and Sandbox (unless permadeath is on, in which case one cannot save), but not The Night Watch. Survival mode focuses more on the game's survival features and requires close attention to the chosen character's physical needs. The player spawns on one of several islands of different sizes (the player can choose from a small, medium or large island) with different layouts; the islands are a mix of the Garden District and Hamlyn Village. The player can choose one of the three characters from the campaign to play as they progress through the campaign. On each Island there are two notable locations (a black circle with an eye on it) which each contain either a bridge key-card or a boat capacitor, and they have to use the key cards to unlock the bridges to the other islands. The player's score depends on how long they survive and if they managed to escape by collecting the five boat capacitors located around the map and repairing a boat in the boat house. The player has to find safe houses on the island, but they cannot sleep in an occupied house (the occupants will awake immediately). They can also fast travel to any safe-house that they have located, from anywhere on the map (unless they are in combat).
== Combination hemoglobinopathies == A combination hemoglobinopathy occurs when someone inherits two different abnormal hemoglobin genes. If these are different versions of the same gene, one having been inherited from each parent it is an example of compound heterozygosity. Some examples of clinically significant combinations involving beta thalassemia include:
== Treatment == There is no cure for VERBAS. In almost all cases, people with VERBAS are able to attend mainstream school with or without supports. Due to the lack of research and rareness of the disorder, there are no developed treatments for it and all treatments are symptomatic.
Fourth, and more debated, article 24 requires that the longer an EU citizen stays in a host state, the more rights they have to access public and welfare services, on the basis of equal treatment. This reflects general principles of equal treatment and citizenship in TFEU articles 18 and 20. In a simple case, in Sala v Freistaat Bayern the Court of Justice held that a Spanish lady who had lived in Germany for 25 years and had a baby was entitled to child support, without the need for a residence permit, because Germans did not need one. In Trojani v Centre public d'aide sociale de Bruxelles, a French man who lived in Belgium for two years was entitled to the "minimex" allowance from the state for a minimum living wage. In Grzelczyk v Centre Public d'Aide Sociale d'Ottignes-Louvain-la-Neuve a French student, who had lived in Belgium for three years, was entitled to receive the "minimex" income support for his fourth year of study. Similarly, in R (Bidar) v London Borough of Ealing the Court of Justice held that it was lawful to require a French UCL economics student lived in the UK for three years before receiving a student loan, but not that he had to have additional "settled status". Similarly, in Commission v Austria, Austria was not entitled to restrict its university places to Austrian students to avoid "structural, staffing and financial problems" if (mainly German) foreign students applied, unless it proved there was an actual problem.
Sources: en.wikipedia.org
by sending weapons to one of the sides) between Russia and Ukraine to negotiate an end to the conflict and invited the US to join Brazil in a new global climate governance On 28 February, Brazilian Environment minister Marina Silva met with John Kerry, the White House envoy for climate change during his visit to Brazil, and announced the resumption of a US-Brazil environment group created in 2015 to debate energy transition, low carbon economy, climate change mitigation, indigenous peoples protection and bioconomy among others between the two countries. Nevertheless, no contribution to the Amazon Fund was announced by Kerry during the visit. In September 2023, Lula and Biden met on the sidelines of the 78th United National General Assembly (UNGA), in New York, to launch an initiative to promote worker's rights. In June 2024, it was reported that Brazil and the US were preparing to launch a joint green transition partnership involving lithium, niobium and other strategic minerals to expand and develop both countries' supply chains.
== Uses == Homoarginine is used clinical studies, often with rats, to explore its effects on cardiovascular health by acting as an inhibitor for organ-specific reactions as well as a stimulator in some cases. A recent study was done on the topic of homoarginine related to heart failure and sudden cardiac death in haemodialysis patients. The study was done on 1255 diabetic haemodialysis patients throughout a median of 4 years of follow-up. Results showed a range of different events such as sudden cardiac death, myocardial infarction, stroke, and even death due to heart failure. The study calculations showed that the risk of sudden cardiac death had a threefold increase in the presence of per unit decrease of homoarginine. This explained the strong association of congestive heart failure and left ventricular hypertrophy with low homoarginine levels. Furthermore, this study presented evidence towards increased risk of stroke with low concentrations of homoarginine. Yet, some cases such as myocardial infarction did not show any significance towards low levels of homoarginine correlation.
On-line mass spectrometry was develop to solve some of the limitations and problem that develop from off-line analysis, such as evaporation and chemical reactions of particles in the filters during long analysis time. On-line Mass spectrometry solves these problems through the collection and analysis of aerosol particles in real time. On-line instruments are very portable and allow for spatial variability to be examined. These portable instruments can be put on many different platforms such as boats, planes, and mobile platforms (e.g. car trailers). An example of this is in the picture at the beginning with the instrumentation attached to an aircraft. Like off-line, on-line mass spectrometry has many different type of instruments, which can be broken up into two types; instruments that measures the chemistry of the particle ensemble (bulk measurement) and those that measure the chemistry of individual particles (single-particle measurement). Thus based on analytical need different instrumentation is used in analysis of the aerosol particles.
== Occurrence == Traces of californium can be found near facilities that use the element in mineral prospecting and in medical treatments. The element is fairly insoluble in water, but it adheres well to ordinary soil; and concentrations of it in the soil can be 500 times higher than in the water surrounding the soil particles. Nuclear fallout from atmospheric nuclear weapons testing prior to 1980 contributed a small amount of californium to the environment. Californium-249, -252, -253, and -254 have been observed in the radioactive dust collected from the air after a nuclear explosion. Californium is not a major radionuclide at United States Department of Energy legacy sites since it was not produced in large quantities. Californium was once believed to be produced in supernovas, as their decay matches the 60-day half-life of 254Cf. However, subsequent studies failed to demonstrate any californium spectra, and supernova light curves are now thought to follow the decay of nickel-56. The transuranic elements up to fermium, including californium, should have been present in the natural nuclear fission reactor at Oklo, but any quantities produced then would have long since decayed away.
1978 Genentech produces biosynthetic human insulin in Escherichia coli bacteria using recombinant DNA techniques, licenses to Eli Lilly 1981 Novo Nordisk chemically and enzymatically converts porcine to human insulin 1982 Genentech synthetic human insulin (above) approved 1983 Eli Lilly and Company produces biosynthetic human insulin with recombinant DNA technology, Humulin 1985 Axel Ullrich sequences a human cell membrane insulin receptor. 1988 Novo Nordisk produces recombinant biosynthetic human insulin 1996 Lilly Humalog "lispro" insulin analogue approved. 2000 Sanofi Aventis Lantus insulin "glargine" analogue approved for clinical use in the US and the EU. 2004 Sanofi Aventis Apidra insulin "glulisine" insulin analogue approved for clinical use in the US. 2006 Novo Nordisk Levemir "detemir" insulin analogue approved for clinical use in the US. 2008 Abbott laboratories " FreeStyle Navigator CGM" gets approved. 2013 The US Food and Drug Administration (FDA) requested more cardiac safety tests for Insulin degludec. 2015 Insulin degludec was approved by the FDA in September 2015.
Sources: en.wikipedia.org
A responder analysis counts participants who cross a threshold, such as five or ten percent weight loss. It complements average percent change by showing how widely results are distributed. The two measures can diverge when a subset of participants loses a large amount.
Mechanistic measures such as energy expenditure and liver fat change come from small substudies and should be read as preliminary. Long-term clinical outcomes are not yet available. Average weight loss figures are better supported than explanations for how the loss is achieved.
Endpoints reported at different weeks, in different baseline BMI ranges, or under different dose-escalation schedules are not directly comparable. Studies in type 2 diabetes often show smaller weight changes than studies in obesity without diabetes. Reporting the population alongside the number keeps comparisons honest.
Retatrutide is an investigational peptide that activates the GLP-1, GIP, and glucagon receptors at the same time. It is being studied for obesity and type 2 diabetes and has not been approved for clinical use. The internal code LY3437943 refers to the same molecule.